Phase 2 N=128 BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Progression-free Survival Rate at 9 Months (PFS-9) — 62.1; 70.2 percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Overall Efficacy, Taking Into Account Both Objective Response and Meaningful Reductions in Tumor Burden That do Not Meet the RECIST Criteria for PR or CR (e.g., 5-30%…
Phase 2 N=29 Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Lymphoma
Primary: Overall Response — 3 participants
Phase 2 N=112 Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Colorectal Cancer · Familial Adenomatous Polyposis
Primary: Percent Change in the Number of Polyps Greater Than or Equal to 2mm in Diameter in Focal Area(s) of the Colorectum — -1; -11; -1; -13 percentage change in polyp count
Phase 2 N=979 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
Pandemic H5N1 Influenza
Primary: Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 4; 4; 85; 63 Percentages of subjects
Phase 2 N=19 Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Objective Response Rate by RECIST Criteria Following — 0 participants
Phase 2 N=755 A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP) — -3.41; -1.70; -0.63 millimeters of mercury (mmHg) — p=<0.001
Phase 2 N=160 Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Moderate-to-Severe Asthma
Primary: Change in Percent Predicted FEV1 at Week 24 — 3.631; 2.000 Percent
Phase 2 N=68 Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression
Depression
Primary: Hamilton Rating Scale for Depression-17 Item Minus Sleep Items — 6.1; 8.1; 6.3 units on a scale — p=.202
Phase 2 N=363 Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
Macular Edema
Primary: Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 60.2; 60.4; 4.34; 7.60 Letters
Phase 2 N=29 Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Neoplasms, Germ Cell and Embryonal
Primary: Twelve Month Disease-free Survival Rate — 3.5 percentage of participants
Phase 2 N=60 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Esophageal Neoplasms · Stomach Neoplasms · Neoplasm Metastasis
Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months
Phase 2 N=21 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants
Phase 2 N=255 Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
Alzheimer Disease · Cognitive Impairment
Primary: Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule — -2.58; -1.39; -1.45 units on…
Phase 2 N=536 Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation
Atrial Fibrillation
Primary: Incidence of Bleeding Events (Major Bleeding, Clinically Relevant Non-major Bleeding and Minor Bleeding ) Identified During the Period From the Entry Into the Treatment…